TNSN04090A1 - Conjugues de l'hormone de croissance humaine chimiquement modifies - Google Patents

Conjugues de l'hormone de croissance humaine chimiquement modifies

Info

Publication number
TNSN04090A1
TNSN04090A1 TNP2004000090A TNSN04090A TNSN04090A1 TN SN04090 A1 TNSN04090 A1 TN SN04090A1 TN P2004000090 A TNP2004000090 A TN P2004000090A TN SN04090 A TNSN04090 A TN SN04090A TN SN04090 A1 TNSN04090 A1 TN SN04090A1
Authority
TN
Tunisia
Prior art keywords
growth hormone
human growth
chemically modified
modified human
hormone conjugates
Prior art date
Application number
TNP2004000090A
Other languages
English (en)
Inventor
Rory F Finn
Wei Lao
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of TNSN04090A1 publication Critical patent/TNSN04090A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENTION DECRIT UNE HORMONE DE CROISSANCE HUMAINE (hGH) MODIFIEE CHIMIQUEMENT PAR LIAISON DE LA PROTEINE AVEC UN POLYMERE SOLUBLE DANS L'EAU. LA PROTEINE MODIFIEE AU SENS DE L'INVENTION; PRESENTE UNE ACTIVITE hGH QUI DURE BEAUCOUP PLUS LONGTEMPS QUE CELLE DE L'HORMONE NON MODIFIEE; CE QUI PERMET D'EN REDUIRE LA DOSE ET LA FREQUENCE D'ADMINISTRATION.
TNP2004000090A 2001-11-20 2004-05-20 Conjugues de l'hormone de croissance humaine chimiquement modifies TNSN04090A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (fr) 2001-11-20 2002-11-20 Conjugues de l'hormone de croissance humaine chimiquement modifiee

Publications (1)

Publication Number Publication Date
TNSN04090A1 true TNSN04090A1 (fr) 2006-06-01

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000090A TNSN04090A1 (fr) 2001-11-20 2004-05-20 Conjugues de l'hormone de croissance humaine chimiquement modifies

Country Status (25)

Country Link
EP (1) EP1453859A2 (fr)
JP (2) JP2005525302A (fr)
KR (2) KR20070072924A (fr)
CN (1) CN1608079A (fr)
AP (1) AP2004003050A0 (fr)
AU (1) AU2002356990A1 (fr)
BR (1) BR0214451A (fr)
CA (1) CA2467731A1 (fr)
CO (1) CO5580794A2 (fr)
EA (2) EA200700431A1 (fr)
EC (1) ECSP045114A (fr)
GE (1) GEP20063860B (fr)
HR (1) HRP20040448A2 (fr)
HU (1) HUP0500997A2 (fr)
IL (1) IL162031A0 (fr)
IS (1) IS7268A (fr)
MA (1) MA27544A1 (fr)
MX (1) MXPA04004809A (fr)
NO (1) NO20042182L (fr)
OA (1) OA13063A (fr)
PL (1) PL374354A1 (fr)
RS (1) RS53104A (fr)
TN (1) TNSN04090A1 (fr)
WO (1) WO2003044056A2 (fr)
ZA (1) ZA200403907B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
DK3025726T3 (da) * 2002-01-18 2019-12-09 Biogen Ma Inc Polyalkylenpolymerforbindelser og anvendelser deraf
KR20050093856A (ko) 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체 알카날
EP1591467A1 (fr) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugue d un polyethylene glycol comprenant un group terminal alcanal et un hormone de croissance humaine
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
JP2008502301A (ja) * 2003-10-10 2008-01-31 ノボ　ノルディスク　アクティーゼルスカブ ペプチドの抱合
CA2552043A1 (fr) * 2004-01-21 2005-08-04 Novo Nordisk A/S Conjugaison de peptides induite par la transglutaminase
CN101010105A (zh) * 2004-08-31 2007-08-01 法玛西雅厄普约翰有限责任公司 甘油支化的聚乙二醇人生长激素缀合物、其制备方法及其使用方法
KR20070090023A (ko) 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
WO2006073846A2 (fr) * 2004-12-22 2006-07-13 Ambrx, Inc. Procedes pour l'expression et la purification d'hormone de croissance humaine recombinante
JP2008531482A (ja) 2005-02-10 2008-08-14 ノボ ノルディスク アクティーゼルスカブ Ｃ末端がｐｅｇ化された成長ホルモン
MX2007012887A (es) 2005-04-18 2007-12-10 Novo Nordisk As Variantes il-21.
JP2009506096A (ja) * 2005-08-30 2009-02-12 ノボ ノルディスク ヘルス ケア アーゲー ペグ化成長ホルモンの液状調製物
PL1954710T3 (pl) * 2005-11-08 2011-09-30 Ambrx Inc Przyspieszacze do modyfikacji aminokwasów niewystępujących w przyrodzie i polipeptydów zbudowanych z aminokwasów nie występujących w przyrodzie
US20080317670A1 (en) 2005-12-14 2008-12-25 Ambrx, Inc. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
EP2040757A2 (fr) 2006-07-07 2009-04-01 Novo Nordisk Health Care AG Nouveaux conjugués de protéines et leurs procédés de préparation
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
AU2008353850B2 (en) * 2008-04-03 2014-08-21 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
AR072850A1 (es) * 2008-07-31 2010-09-22 Pharmaessentia Corp Conjugados peptido-polimero
WO2010015668A1 (fr) 2008-08-06 2010-02-11 Novo Nordisk A/S Protéines conjuguées à efficacité in vivo prolongée
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
US8492503B2 (en) * 2008-09-11 2013-07-23 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
AU2010207725B2 (en) 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
AU2010332958B2 (en) 2009-12-15 2014-09-18 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
CA2787895A1 (fr) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Composes stables d'hormone de croissance
AU2011208625C1 (en) 2010-01-22 2022-08-18 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
CN103119055A (zh) * 2010-05-17 2013-05-22 塞比克斯公司 聚乙二醇化c肽
EP2446898A1 (fr) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Utilisation de l'hormone de croissance pour améliorer la réponse immunitaire chez des patients immunodéprimés
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
KR102540109B1 (ko) 2014-11-06 2023-06-02 파마에센시아 코퍼레이션 Peg화된 인터페론의 투약 요법
EP3220892B1 (fr) 2014-11-21 2021-10-13 Ascendis Pharma Endocrinology Division A/S Formes posologiques de l'hormone de croissance à action prolongée
MA41957A (fr) * 2015-03-11 2018-02-28 Nektar Therapeutics Conjugués d'une fraction d'il-7 et d'un polymère
NZ740534A (en) * 2015-09-18 2019-07-26 Univ Miyazaki Long-acting adrenomedullin derivative
CN114539384B (zh) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
EP0458064B1 (fr) * 1990-05-04 1998-02-25 American Cyanamid Company Stabilisation de la somatotropine à travers une modification des résidus de cystéine
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
WO1993000109A1 (fr) * 1991-06-28 1993-01-07 Genentech, Inc. Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DK1568772T3 (da) * 1995-09-21 2010-10-18 Genentech Inc Varianter af humant væksthormon
ES2297889T3 (es) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
CA2359345A1 (fr) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Techniques permettant de produire des proteines contenant des residus cysteine libres
CN1376164A (zh) * 1999-01-29 2002-10-23 霍夫曼-拉罗奇有限公司 Gcsf缀合物
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
AU2002219021A1 (en) * 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
PL374354A1 (en) 2005-10-17
MXPA04004809A (es) 2004-08-11
EA200700431A1 (ru) 2008-02-28
AP2004003050A0 (en) 2004-06-30
BR0214451A (pt) 2006-05-30
JP2006321808A (ja) 2006-11-30
JP2005525302A (ja) 2005-08-25
KR20050044858A (ko) 2005-05-13
KR20070072924A (ko) 2007-07-06
ECSP045114A (es) 2004-07-23
ZA200403907B (en) 2007-12-27
EA008505B1 (ru) 2007-06-29
IL162031A0 (en) 2005-11-20
HRP20040448A2 (en) 2006-02-28
WO2003044056A3 (fr) 2003-08-21
IS7268A (is) 2004-05-17
WO2003044056A2 (fr) 2003-05-30
GEP20063860B (en) 2006-06-26
HUP0500997A2 (en) 2007-11-28
AU2002356990A1 (en) 2003-06-10
EA200400565A1 (ru) 2005-06-30
CA2467731A1 (fr) 2003-05-30
CN1608079A (zh) 2005-04-20
MA27544A1 (fr) 2005-10-03
CO5580794A2 (es) 2005-11-30
EP1453859A2 (fr) 2004-09-08
NO20042182L (no) 2004-08-11
RS53104A (en) 2006-10-27
OA13063A (en) 2006-11-10

Similar Documents

Publication Publication Date Title
TNSN04090A1 (fr) Conjugues de l'hormone de croissance humaine chimiquement modifies
RU2227042C2 (ru) Композиции и способы системной доставки пероральных вакцин и терапевтических агентов
CY1118991T1 (el) Φαρμακοτεχνικη μορφη ανθρωπινων αντισωματων για θεραπεια σχετικων με tnf-αλφα διαταραχων
DE3774274D1 (de) Solubilisierung von proteinen fuer pharmazeutsche zusammensetzungen.
NO20064676L (no) Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre
SE8902638D0 (sv) Stabilized protein or peptide conjugates
EA200300856A1 (ru) Долгоживущие производные рилизинг-фактора гормона роста
EA199900979A1 (ru) Композиции активированного протеина
NO20061489L (no) Formuleringer og fremgangsmater for a behandle inflamatorisk tarmsykdom
HUP0004924A2 (hu) Ciklodextrineket tartalmazó gyógyászati készítmények
WO1998051325A3 (fr) Peptides aleatoires se liant au recepteurs de transport du tractus gastrointestinal (git) et procedes y relatifs
EP2278003A3 (fr) Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
BR0109704A (pt) Método de tratamento usando conjugados de imunógeno ligando
DE60321825D1 (de) Maleinsäureamid polymerderivate und ihre biokonjugate
ATE410979T1 (de) Vorrichtung zur befestigung und verankerung von herzklappenprothesen
TNSN95061A1 (fr) Derives d'oxalylamino-benzofuranne et benzothienyle
EE200100507A (et) Hüdroksümatairesinool vähkkasvaja vältimises
BR0316716A (pt) Conjugados quimicamente modificados do hormÈnio do crescimento humano
AU7814498A (en) Multivalent (in ovo) avian vaccine
PT1098643E (pt) Fenilacetilglutamina fenilacetilisoglutamina e/ou fenilacetato para o tratamento de doencas neoplasicas
NO20023464D0 (no) Sammensetning for intestinal avlevering
US20050065113A1 (en) Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
DK0981362T3 (da) Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal
WO2000006185A3 (fr) Procedes d'utilisation d'un analogue de somatostatine